Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation
BMI1 and CHD7 are chromatin remodelling genes with a role in medulloblastoma pathogenesis. Here, the authors demonstrate that the BMI1High/CHD7Low signature mediates metabolic adaptation in G4 MB and predicts response to inositol treatment either alone or in combination with chemotherapy.
Guardado en:
Autores principales: | Sara Badodi, Nicola Pomella, Xinyu Zhang, Gabriel Rosser, John Whittingham, Maria Victoria Niklison-Chirou, Yau Mun Lim, Sebastian Brandner, Gillian Morrison, Steven M. Pollard, Christopher D. Bennett, Steven C. Clifford, Andrew Peet, M. Albert Basson, Silvia Marino |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e099abd2067e489ba7b766a7107a8238 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The transcriptional landscape of Shh medulloblastoma
por: Patryk Skowron, et al.
Publicado: (2021) -
Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
por: Manon Penco-Campillo, et al.
Publicado: (2020) -
Wnt activation as a therapeutic strategy in medulloblastoma
por: Branavan Manoranjan, et al.
Publicado: (2020) -
Modeling medulloblastoma in vivo and with human cerebellar organoids
por: Claudio Ballabio, et al.
Publicado: (2020) -
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
por: Marcel Kool, et al.
Publicado: (2008)